Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Total Non-Current Liabilities (2024 - 2025)

Historic Total Non-Current Liabilities for Century Therapeutics (IPSC) over the last 2 years, with Q3 2025 value amounting to $67.6 million.

  • Century Therapeutics' Total Non-Current Liabilities fell 6325.86% to $67.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.6 million, marking a year-over-year decrease of 6325.86%. This contributed to the annual value of $183.1 million for FY2024, which is N/A changed from last year.
  • Per Century Therapeutics' latest filing, its Total Non-Current Liabilities stood at $67.6 million for Q3 2025, which was down 6325.86% from $65.9 million recorded in Q2 2025.
  • Century Therapeutics' 5-year Total Non-Current Liabilities high stood at $185.0 million for Q2 2024, and its period low was $65.9 million during Q2 2025.